A recall has been issued for a widely prescribed blood pressure medication due to potential cross-contamination issues. Glenmark Pharmaceuticals Inc. has announced the recall of over 11,100 bottles of their bisoprolol fumarate and hydrochlorothiazide tablets, marketed under the brand name Ziac.
Details of the Recall
This recall was prompted by concerns that the tablets may have been contaminated with another drug. According to the recall notice released by the Food and Drug Administration (FDA), testing of reserve samples indicated the presence of ezetimibe, a medication used to manage high cholesterol.
Medication Information
- Brand Name: Ziac
- Active Ingredients: Bisoprolol fumarate and hydrochlorothiazide
- Dosages: Available in 2.5 mg and 6.25 mg
Recall Classification
The FDA classified this recall as Class III, meaning that exposure to the affected medication is unlikely to result in adverse health effects. Despite this classification, it raises concerns for patients taking the affected products.
Affected Products
The recall affects specific package sizes and lot numbers:
- 30-count bottles: NDC-68462-878-30
- 100-count bottles: NDC-68462-878-01
- 500-count bottles: NDC-68462-878-05
These products have expiration dates ranging from November 2025 to May 2026, with a total of 11,136 bottles involved in the recall.
Next Steps for Patients
The FDA has not provided specific guidance for patients whose medications are included in the recall. In light of these developments, patients are advised to consult their healthcare providers for further assistance.
For more updates on health-related issues, stay tuned to El-Balad for the latest information and expert analysis.
